2026 U.S. Life Sciences Trends

The U.S. Life Sciences Real Estate Market Is Approaching a Turning Point

After two years of oversupply, cautious decision-making and stalled capital markets activity, the life sciences real estate market is starting to see green shoots.

Demand for space has stabilized. The construction pipeline is receding. And investors are re-engaging. Together, these shifts are laying the groundwork for a more disciplined—and potentially more opportunistic—phase of the cycle in 2026.

But the recovery isn’t uniform. A raft of expiring patents, accelerating scientific innovation, surging domestic manufacturing and rising global competition stand to reshape the sector and its real estate.

The question for investors is where, when and how the life sciences real estate recovery unfolds?

Key Takeaways

• Construction Is Projected to Hit a 10-Year Low: A pullback in lab and R&D construction activity is easing the pressure in major U.S. life sciences markets and setting the stage for healthier fundamentals.
• Key Indicators Are Trending Upward: Multiple data points moved in positive directions at the end of 2025 and are projected to improve further in 2026, signaling a shift in the cycle.
• Capital Is Re‑Engaging: Equity market gains and renewed venture capital activity have historically preceded a rise in lab demand—and both were on the upswing heading into 2026.
• Investment Activity Is Poised to Re-Accelerate: As policy uncertainty fades and financing conditions improve, life sciences real estate transaction volume is expected to gain momentum in key markets.
• Companies Are Investing at Historic Levels: Lab facility investments have reached unprecedented levels, reinforcing the nation’s position as a global life sciences hub.
• Industry Megatrends Are Reshaping Demand: A historically steep patent cliff, faster drug approvals, more funding sources and China’s expanding role in global R&D will drive uneven demand patterns, creating both opportunities and risk for investors.